Clinical Trial Update: A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab [Phase 2]

View source ↗

Summary

Phase 2 trial investigating rituximab (anti-CD20) as a protocol-based treatment for early and severe systemic sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Early and Severe Systemic Sclerosis | Phase 2 | Status: COMPLETED